


**Conditional Request For Constructive Assistance**

Applicant has amended the claims of this application so that they are proper, definitive, and define a novel method which is also unobvious. If, for any reason this application is not believed to be in full condition for allowance, applicant respectfully requests the constructive assistance and suggestions of the Examiner pursuant to M.P.E.P. 706.03(d) and 707.07(j) in order that the undersigned can place this application in allowable condition as soon as possible and without the need for further proceedings.

Very respectfully,



Mark Zamoyski  
Applicant Pro Se  
988 Foothill Drive, San Jose, CA 95123  
Tel: 408-365-1170 Fax: 408-365-9898

**Certificate of Mailing:** Deposited with the U.S. Postal Service as express mail in an envelope addressed to: "MAIL STOP NON-FEE AMENDMENTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450"

Express Mail Label #

EQ169790805US

Date Mailed:

7/26/05

## EXHIBIT A: Comparative PSR Potency and Safety for Representative Trichothecenes

MOLECULE DESCRIPTIONHuman Lung Dose/SafetyID 50  
(ng/ml)LD 50  
(in mg/kg BW)

Lung Dose 3X ID50 (in ng.)	LD 50 (in ng.)	Times Safer
5760	294000000	51,042
8280	840000000	101,449
187200	1015000000	5,422

IV	IP
4.2	5.2
12	15
	14.5

HEp2 /HSV2
1.6
2.3
52

Molecular Formula	Molec. Mass	Mlt Pt (°C)	CAS Number
C24 H34 O9	466	151	21259-20-1
C19 H26 O7	366	162	2270-40-8
C19 H26 O8	382	171	36519-25-2

Type B

DON (Deoxynivalenol)	C15 H20 O6	296	151	51481-10-8
NIV (Nivalenol)	C15 H20 O7	312	222	23282-20-4
FusX (Fusarenon - X)	C17 H22 O8	354	91	23255-69-8

Type C

Crotocin		250		
----------	--	-----	--	--

Macrocyclic

Satratoxin G	C29 H36 O10		1.5		5400	70000000	
Satratoxin H	C29 H36 O9	528	1.4	1	5040	70000000	13,889
Roridin A	C29 H40 O9	532	1	1.5	3600	105000000	29,167
Verrucarin A	C27 H34 O9	502	41	0.5	147600		
Baccharinoid B-4			9		32400		
Baccharinoid B-5							

## Notes &amp; Abbreviations:

Cell line origin: HEp2 = epidermoid carcinoma

Administration Route: IV = intravenous, IP = intraperitoneal

ID 50 for cells: concentration required for 50% protein synthesis inhibition in cultured human epidermoid cell lines - HSV protein synthesis inhibition model used

Administration Route: IV = intravenous, IP = intraperitoneal

LD 50 based on mouse models

Human Lung Dose/Safety: 3 times ID50 used for ~ complete protein synthesis restriction (PSR), 1200 grams = average human lung

LD50 based on avg. 70 KG human, IV LD 50 used when available, otherwise IP LD 50 used

Times safer = LD 50 in ng + 3X ID 50 lung dose in ng. (in animal models 5 X safer = no mortality)